期刊
LEUKEMIA & LYMPHOMA
卷 56, 期 3, 页码 730-738出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2014.928934
关键词
CPT; imatinib resistance; synergism; Bcr/Abl pathway
资金
- National Natural Science Foundation of China [81202820, 81303269]
- Zhejiang Provincial Natural Science Foundation of China [Q12H28005]
- Zhejiang Provincial Administration of Traditional Chinese Medicine [2012ZQ006, 2011ZA081]
Imatinib resistance has emerged as a significant clinical problem in chronic myeloid leukemia (CML) treatment. In this study, we investigated the effect and mechanism of combination treatment with imatinib and cryptotanshinone (CPT) in CML cells. Cotreatment with imatinib and CPT showed a significant synergistic killing effect in both imatinib sensitive and resistant CML cell lines, as well as primary CML cells. Furthermore, combination treatment induced apoptosis significantly, as indicated by increases in apoptotic cell fraction and activities of proapoptotic proteins. Subsequent studies revealed that CPT significantly inhibited Bcr/Abl protein expression, as well as phosphorylation expression levels of signal transducer and activator of transcription 3 (STAT3), mammalian target of rapamycin (mTOR) and eukaryotic translation initiation factor 4E (eIF4E), which are critical mediators of Bcr/Abl transformation. Furthermore, CPT in combination with imatinib dramatically decreased the activity of the Bcr/Abl pathway in both K562 and K562-R cells. Our results demonstrated that CPT increased imatinib-induced apoptosis in a Bcr/Abl dependent manner, suggesting a novel strategy for the treatment of CML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据